New trial
Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
- Trial ID
- NCT06959641 on ClinicalTrials.gov
- Cancer type
- Thyroid Cancer
- Published in
- New in Oncology - May 21, 2025
This phase II trial is evaluating XL092, a tyrosine kinase inhibitor, as first-line therapy for advanced thyroid cancer that no longer responds to radioiodine treatment. Patients receive daily oral dosing with regular imaging and biospecimen assessments to monitor treatment response.
More in thyroid cancer
-
Trial result · Oct 22, 2026 · NCT03899792
Selpercatinib (selective RET inhibitor) posts 53% ORR with 2-year durability in pediatric RET-altered tumors -
Trial result · Aug 13, 2026 · NCT04940052
Dabrafenib + trametinib (BRAF/MEK) cuts progression risk in BRAF V600E thyroid cancer -
Trial result · Aug 13, 2026 · NCT03181100
Atezolizumab (PD-L1) + MAPK-targeted therapy links ATC long survival to “inflamed + differentiated” tumors, not BRAF/RAS status -
Trial result · Jul 8, 2026 · NCT03037385
Pralsetinib (selective RET inhibitor) drives 92% ORR in pretreated RET fusion+ thyroid cancer; 68% ORR in RET-altered MTC -
Trial result · Jul 8, 2026 · NCT03669432
THYRO-RT Finds No Significant LRR Benefit From Adjuvant EBRT in High-Risk Thyroid Cancer